The potential of serum neurofilament as biomarker for multiple sclerosis
Open accessThe DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal damage as well as its quantification is a critical step for patients. Blood-based serum neurofilament light chain (sNfL) is currently under close investigation as an easily accessible biomarker of prognosis and treatment response in patients with multiple sclerosis. There is abundant evidence that sNfL levels reflect ongoing inflammatory-driven neuroaxonal damage (e.g. relapses or MRI disease activity) and that sNfL levels predict disease activity over the next few years. In contrast, the association of sNfL with long-term clinical outcomes or its ability to reflect slow, diffuse neurodegenerative damage in multiple sclerosis is less clear. However, early results from real-world cohorts and clinical trials using sNfL as a marker of treatment response in multiple sclerosis are encouraging. Importantly, clinical algorithms should now be developed that incorporate the routine use of sNfL to guide individualized clinical decision-making in people with multiple sclerosis, together with additional fluid biomarkers and clinical and MRI measures. Here, we propose specific clinical scenarios where implementing sNfL measures may be of utility, including, among others: initial diagnosis, first treatment choice, surveillance of subclinical disease activity and guidance of therapy selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reich, D. S., Lucchinetti, C. F., & Calabresi, P. A. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1401483 · Cited by 2,491
Rissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1641 · Cited by 2,119
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988
Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis
Disanto, G., Barro, C., Benkert, P., Naegelin, Y., Schädelin, S., Giardiello, A., Zecca, C., Blennow, K., Zetterberg, H., Leppert, D., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24954 · Cited by 1,164
Bridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the NFL Group, Alvarez-Cermeño, J. C., Andreasson, U., Axelsson, M., Bäckström, D. C., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1534 · Cited by 764 · cited 2×
“than 30 different neurological disorders revealed increased levels compared with healthy controls in most cases.(6) High NfL levels are”
BackgroundResultKuhle, J., Barro, C., Andreasson, U., Derfuss, T., Lindberg, R., Sandelius, Å., Liman, V., Norgren, N., Blennow, K., & Zetterberg, H. (2016) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2015-1195 · Cited by 740
Kappos, L., Wolinsky, J. S., Giovannoni, G., Arnold, D. L., Wang, Q., Bernasconi, C., Model, F., Koendgen, H., Manfrini, M., Belachew, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1568 · Cited by 658
Khalil, M., Pirpamer, L., Hofer, E., Voortman, M. M., Barro, C., Leppert, D., Benkert, P., Ropele, S., Enzinger, C., Fazekas, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14612-6 · Cited by 572
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Kuhle, J., Kropshofer, H., Haering, D. A., Kundu, U., Meinert, R., Barro, C., Dahlke, F., Tomic, D., Leppert, D., & Kappos, L. (2019) · Neurology · doi:10.1212/wnl.0000000000007032 · Cited by 568
Barro, C., Benkert, P., Disanto, G., Tsagkas, C., Amann, M., Naegelin, Y., Leppert, D., Gobbi, C., Granziera, C., Yaldizli, Ö., et al. (2018) · Brain · doi:10.1093/brain/awy154 · Cited by 517
Miller, D. H., Chard, D. T., & Ciccarelli, O. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70274-5 · Cited by 507
Rosengren, L. E., Karlsson, J., Karlsson, J., Persson, L. I., & Wikkelsø, C. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67052013.x · Cited by 499
Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis
Dutta, R., & Trapp, B. D. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.09.005 · Cited by 457 · cited 1×
“This is in line with positive correlations between the inflammatory activity of multiple sclerosis lesions and axonal damage.(59) Over a relatively short period, high sNfL levels were associated with an increased risk for relapses and/or EDSS deterioration over the next 1–3 years.”
ResultMonitoring disease activity in multiple sclerosis using serum neurofilament light protein
Novakova, L., Zetterberg, H., Sundström, P., Axelsson, M., Khademi, M., Gunnarsson, M., Malmeström, C., Svenningsson, A., Olsson, T., Piehl, F., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004683 · Cited by 426
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab
Gunnarsson, M., Malmeström, C., Axelsson, M., Sundström, P., Dahle, C., Vrethem, M., Olsson, T., Piehl, F., Norgren, N., Rosengren, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22247 · Cited by 345
Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis
Lycke, J. N., Karlsson, J.-E., Andersen, O., & Rosengren, L. E. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.3.402 · Cited by 314
Measurement and clinical effect of grey matter pathology in multiple sclerosis
Geurts, J. J., Calabrese, M., Fisher, E., & Rudick, R. A. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70230-2 · Cited by 298 · cited 1×
“This notion is further supported by pathological concepts preferentially linking grey matter damage and network dysfunction to cognitive impairment.(66,67) Further studies should therefore focus on developing multi-modal approaches integrating sNfL levels with MRI data and other molecular biomarkers indicative of grey…”
BackgroundInflammatory intrathecal profiles and cortical damage in multiple sclerosis
Magliozzi, R., Howell, O. W., Nicholas, R., Cruciani, C., Castellaro, M., Romualdi, C., Rossi, S., Pitteri, M., Benedetti, M. D., Gajofatto, A., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25197 · Cited by 298
Blood neurofilament light: a critical review of its application to neurologic disease
Barro, C., Chitnis, T., & Weiner, H. L. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51234 · Cited by 296 · cited 1×
“Reassuringly, consistent reports have demonstrated that sNfL is not impacted by sex in healthy cohorts or in patients with multiple sclerosis.(25) However, the physiological increase in sNfL levels seen with ageing in healthy individuals(54,79,80) needs to be taken into consideration when interpreting sNfL data.”
BackgroundSerum GFAP as a biomarker for disease severity in multiple sclerosis
Abdelhak, A., Huss, A., Kassubek, J., Tumani, H., & Otto, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-33158-8 · Cited by 291 · cited 2×
“Early studies in patients with multiple sclerosis suggested that GFAP is not elevated in association with acute relapses and focal inflammatory infiltrates, and hence could be used to elucidate the ongoing glial-driven neurodegenerative pathology.(68,70) Indeed, using diffusion tensor imaging as a means to assess diff…”
BackgroundSerum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis
Bjornevik, K., Munger, K. L., Cortese, M., Barro, C., Healy, B. C., Niebuhr, D. W., Scher, A. I., Kuhle, J., & Ascherio, A. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.3238 · Cited by 269 · cited 1×
“sNfL levels were already elevated 6 years (range: 4–10 years) prior to disease onset and showed a further increase in the years leading up to the first clinical symptoms.(37) Other studies have investigated patients with radiologically isolated syndrome, who are clinically asymptomatic patients undergoing MRI examinat…”
BackgroundSerum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest
Moseby-Knappe, M., Mattsson, N., Nielsen, N., Zetterberg, H., Blennow, K., Dankiewicz, J., Dragancea, I., Friberg, H., Lilja, G., Insel, P. S., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2018.3223 · Cited by 264
Body fluid biomarkers in multiple sclerosis
Comabella, M., & Montalban, X. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70233-3 · Cited by 258
Kuhle, J., Barro, C., Disanto, G., Mathias, A., Soneson, C., Bonnier, G., Yaldizli, Ö., Regeniter, A., Derfuss, T., Canales, M., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515623365 · Cited by 257
Neurofilament and glial fibrillary acidic protein in multiple sclerosis
Norgren, N., Sundström, P., Svenningsson, A., Rosengren, L., Stigbrand, T., & Gunnarsson, M. (2004) · Neurology · doi:10.1212/01.wnl.0000142988.49341.d1 · Cited by 241 · cited 1×
“Early studies in patients with multiple sclerosis suggested that GFAP is not elevated in association with acute relapses and focal inflammatory infiltrates, and hence could be used to elucidate the ongoing glial-driven neurodegenerative pathology.(68,70) Indeed, using diffusion tensor imaging as a means to assess diff…”
BackgroundSerum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD
Watanabe, M., Nakamura, Y., Michalak, Z., Isobe, N., Barro, C., Leppert, D., Matsushita, T., Hayashi, F., Yamasaki, R., Kuhle, J., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008160 · Cited by 220
Siller, N., Kuhle, J., Muthuraman, M., Barro, C., Uphaus, T., Groppa, S., Kappos, L., Zipp, F., & Bittner, S. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458518765666 · Cited by 205 · cited 1×
“It is currently unclear whether blood-brain barrier damage in acute lesions facilitates efflux of sNfL proteins into the peripheral blood thereby resulting in higher absolute levels.(8,9,15,21,23,43,44) EDSS + + Large well-powered studies have clarified that sNfL and current EDSS scores are weakly, yet significantly c…”
BackgroundSelf-citationCombination of CSF N -acetylaspartate and neurofilaments in multiple sclerosis
Teunissen, C. E., Iacobaeus, E., Khademi, M., Brundin, L., Norgren, N., Koel-Simmelink, M. J. A., Schepens, M., Bouwman, F., Twaalfhoven, H. A. M., Blom, H. J., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a0fe3f · Cited by 205
Serum neurofilament is associated with progression of brain atrophy and disability in early MS
Kuhle, J., Nourbakhsh, B., Grant, D., Morant, S., Barro, C., Yaldizli, Ö., Pelletier, D., Giovannoni, G., Waubant, E., & Gnanapavan, S. (2017) · Neurology · doi:10.1212/wnl.0000000000003653 · Cited by 203 · cited 2×
“It is plausible that high sNfL levels precede visual structural alterations in MRI, while exact time frames are still unclear.(46,49,51) Long-term EDSS progression (45 years) and SPMS conversion + The long-term predictive value of sNfL values is so far not consistent in all studies.”
BackgroundCantó, E., Barro, C., Zhao, C., Caillier, S. J., Michalak, Z., Bove, R., Tomic, D., Santaniello, A., Häring, D. A., Hollenbach, J., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2137 · Cited by 199 · cited 5×
“Since then, a broad number of studies have confirmed that sNfL values from patients receiving immunomodulatory drugs are generally lower than untreated patients and that initiation of any treatment is associated with a decrease in sNfL levels.(8,9,15,21,24,82,83) Early studies suggest that sNfL levels might be able to…”
BackgroundResultInfluentialPiehl, F., Kockum, I., Khademi, M., Blennow, K., Lycke, J., Zetterberg, H., & Olsson, T. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458517715132 · Cited by 182
Biomarkers in multiple sclerosis
Housley, W. J., Pitt, D., & Hafler, D. A. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.06.015 · Cited by 181
Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity
Högel, H., Rissanen, E., Barro, C., Matilainen, M., Nylund, M., Kuhle, J., & Airas, L. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458518819380 · Cited by 168 · cited 2×
“These concepts were further expanded by efforts combining sNfL with GFAP, emphasizing that a combination of both markers might be useful in differentiating RRMS from SPMS patients.(69) This notion is supported by an independent report that assessed GFAP and chitinase-3-like protein 1 (CHI3L1) as markers of astrocytic…”
BackgroundResultNeurofilament light chain predicts disease activity in relapsing-remitting MS
Varhaug, K. N., Barro, C., Bjørnevik, K., Myhr, K.-M., Torkildsen, Ø., Wergeland, S., Bindoff, L. A., Kuhle, J., & Vedeler, C. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000422 · Cited by 164 · cited 5×
“the CSF compartment, but also subsequently in low amounts ( 2%) into the peripheral blood.(8,9) Research on neurofilament proteins has been performed for more than 20 years,(10,11) but was initially limited with respect to translational suitability due to the”
BackgroundResultInfluentialMatute-Blanch, C., Villar, L. M., Álvarez-Cermeño, J. C., Rejdak, K., Evdoshenko, E., Makshakov, G., Nazarov, V., Lapin, S., Midaglia, L., Vidal-Jordana, A., et al. (2018) · Brain · doi:10.1093/brain/awy021 · Cited by 161 · cited 1×
“In patients with radiologically isolated syndrome, elevated sNfL levels indicate a higher risk for developing either clinically isolated syndrome (CIS) or multiple sclerosis in the future.(38) These studies from presymptomatic patients with multiple sclerosis underscore the long prodromal phase of this disease prior t…”
BackgroundSelf-citationSerum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis
Thebault, S., Abdoli, M., Fereshtehnejad, S.-M., Tessier, D., Tabard-Cossa, V., & Freedman, M. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-67504-6 · Cited by 161 · cited 1×
“16 over a median follow-up of 19 years.(55,56) In one large study in 44000 patients and a median follow-up of 5 years, high sNfL levels were associated with the risk of reaching an EDSS score of 3.”
BackgroundSerum neurofilament light as a biomarker in progressive multiple sclerosis
Kapoor, R., Smith, K. E., Allegretta, M., Arnold, D. L., Carroll, W., Comabella, M., Furlan, R., Harp, C., Kuhle, J., Leppert, D., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010346 · Cited by 156
Uphaus, T., Bittner, S., Gröschel, S., Steffen, F., Muthuraman, M., Wasser, K., Weber-Krüger, M., Zipp, F., Wachter, R., & Gröschel, K. (2019) · Stroke · doi:10.1161/strokeaha.119.026410 · Cited by 154
Self-citationNeurofilament light chain serum levels correlate with 10‐year MRI outcomes in multiple sclerosis
Chitnis, T., Gonzalez, C., Healy, B. C., Saxena, S., Rosso, M., Barro, C., Michalak, Z., Paul, A., Kivisakk, P., Diaz‐Cruz, C., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.638 · Cited by 149 · cited 3×
“A small study in 27 patients did not find correlations between sNfL levels and symbol digit modalities test (SDMT) scores after 1 and 10 years, while other studies demonstrated an association between serum and CSF NfL levels and lower verbal fluency performance or SDMT scores.(52,62,63) In one larger study using BICAM…”
ResultVågberg, M., Norgren, N., Dring, A., Lindqvist, T., Birgander, R., Zetterberg, H., & Svenningsson, A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135886 · Cited by 141
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome
Disanto, G., Adiutori, R., Dobson, R., Martinelli, V., Dalla Costa, G., Runia, T., Evdoshenko, E., Thouvenot, E., Trojano, M., Norgren, N., et al. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309690 · Cited by 140
Blood neurofilament light levels segregate treatment effects in multiple sclerosis
Delcoigne, B., Manouchehrinia, A., Barro, C., Benkert, P., Michalak, Z., Kappos, L., Leppert, D., Tsai, J. A., Plavina, T., Kieseier, B. C., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009097 · Cited by 139
Magliozzi, R., Howell, O. W., Durrenberger, P., Aricò, E., James, R., Cruciani, C., Reeves, C., Roncaroli, F., Nicholas, R., & Reynolds, R. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1650-x · Cited by 129 · cited 1×
“Parvalbumin is a protein expressed in GABAergic interneurons and has been proposed as a marker of cortical grey matter neurodegeneration in patients with multiple sclerosis.(77,78) A reduction in CSF parvalbumin correlated with meningeal inflammation, cortical lesion load, cortical thickness and cognitive impairment;…”
BackgroundBittner, S., Steffen, F., Uphaus, T., Muthuraman, M., Fleischer, V., Salmen, A., Luessi, F., Berthele, A., Klotz, L., Meuth, S. G., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102807 · Cited by 128 · cited 10×
“Since then, a broad number of studies have confirmed that sNfL values from patients receiving immunomodulatory drugs are generally lower than untreated patients and that initiation of any treatment is associated with a decrease in sNfL levels.(8,9,15,21,24,82,83) Early studies suggest that sNfL levels might be able to…”
BackgroundMethodResultInfluentialSelf-citationFarina, G., Magliozzi, R., Pitteri, M., Reynolds, R., Rossi, S., Gajofatto, A., Benedetti, M. D., Facchiano, F., Monaco, S., & Calabrese, M. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0812-y · Cited by 127 · cited 1×
“Patients that are positive for oligoclonal bands have higher serum and CSF NfL levels in comparison with oligoclonal band-negative patients.(74,75) In one study of 142 patients, sNfL values were associated with CSF total CD80 + (i.”
ResultNeurofilament light chain level is a weak risk factor for the development of MS
Arrambide, G., Espejo, C., Eixarch, H., Villar, L. M., Alvarez-Cermeño, J. C., Picón, C., Kuhle, J., Disanto, G., Kappos, L., Sastre-Garriga, J., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003085 · Cited by 110
Jakimovski, D., Zivadinov, R., Ramanthan, M., Hagemeier, J., Weinstock‐Guttman, B., Tomic, D., Kropshofer, H., Fuchs, T. A., Barro, C., Leppert, D., et al. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519881428 · Cited by 110 · cited 1×
“In three studies, sNfL was not associated with EDSS-progression over 5 years(48) and 10 years(24,53), whereas a correlation was observed in other 5-year studies.(53,60) In a study of more than 120 patients, initial sNfL levels were not correlated with EDSS values after 10 years, but did predict T2 lesion load and brai…”
ResultSejbaek, T., Nielsen, H. H., Penner, N., Plavina, T., Mendoza, J. P., Martin, N. A., Elkjaer, M. L., Ravnborg, M. H., & Illes, Z. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-321321 · Cited by 108 · cited 1×
“Since then, a broad number of studies have confirmed that sNfL values from patients receiving immunomodulatory drugs are generally lower than untreated patients and that initiation of any treatment is associated with a decrease in sNfL levels.(8,9,15,21,24,82,83) Early studies suggest that sNfL levels might be able to…”
BackgroundComparison of Simoa TM and Ella TM to assess serum neurofilament‐light chain in multiple sclerosis
Gauthier, A., Viel, S., Perret, M., Brocard, G., Casey, R., Lombard, C., Laurent‐Chabalier, S., Debouverie, M., Edan, G., Vukusic, S., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51355 · Cited by 108
Serum biomarkers in myelin oligodendrocyte glycoprotein antibody–associated disease
Kim, H., Lee, E., Kim, S., Choi, L., Kim, K., Kim, H. W., Kim, K., & Lim, Y. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000708 · Cited by 103
Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
Manouchehrinia, A., Stridh, P., Khademi, M., Leppert, D., Barro, C., Michalak, Z., Benkert, P., Lycke, J., Alfredsson, L., Kappos, L., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009571 · Cited by 94 · cited 3×
“sNfL levels predicted the transition from RRMS to secondary progressive multiple sclerosis (SPMS) in two 5-year follow-up studies,(51,53) whereas other studies did not find a significant relationship between sNfL and the risk of SPMS conversion.(48,54) In three studies, sNfL was not associated with EDSS-progression ov…”
ResultJakimovski, D., Kühle, J., Ramanathan, M. K., Barro, C., Tomic, D., Hagemeier, J., Kropshofer, H., Bergsland, N., Leppert, D., Dwyer, M. G., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50872 · Cited by 92
Prognostic value of serum neurofilaments in patients with clinically isolated syndromes
Costa, G. D., Martinelli, V., Sangalli, F., Moiola, L., Colombo, B., Radaelli, M., Leocani, L., Furlan, R., & Comı, G. (2019) · Neurology · doi:10.1212/wnl.0000000000006902 · Cited by 89
Serum Neurofilament Light Chain Measurement in MS: Hurdles to Clinical Translation
Thebault, S., Booth, R. A., Rush, C., MacLean, H. J., & Freedman, M. S. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.654942 · Cited by 87
Neurofilaments and 10-year follow-up in multiple sclerosis
Bhan, A., Jacobsen, C., Myhr, K. M., Dalen, I., Lode, K., & Farbu, E. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518782005 · Cited by 87 · cited 1×
“In three studies, sNfL was not associated with EDSS-progression over 5 years(48) and 10 years(24,53), whereas a correlation was observed in other 5-year studies.(53,60) In a study of more than 120 patients, initial sNfL levels were not correlated with EDSS values after 10 years, but did predict T2 lesion load and brai…”
ResultUher, T., McComb, M., Galkin, S., Srpova, B., Oechtering, J., Barro, C., Tyblova, M., Bergsland, N., Krasensky, J., Dwyer, M., et al. (2021) · Multiple Sclerosis Journal · doi:10.1177/1352458520912379 · Cited by 86 · cited 4×
“As sNfL indicates acute ongoing axonal damage, existing lesions without ongoing pathology are less likely to contribute to sNfL level increase.(8,23,47) Relapses and EDSS increase in the next 1–3 years + + + High sNfL levels were consistently associated with an increased risk for relapses in the next years.”
BackgroundResultInfluentialTemporal association of sNfL and gad‐enhancing lesions in multiple sclerosis
Rosso, M., Gonzalez, C. T., Healy, B. C., Saxena, S., Paul, A., Bjørnevik, K., Kühle, J., Benkert, P., Leppert, D., Guttmann, C. R. G., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51060 · Cited by 82 · cited 1×
“Here it should be noted that sNfL levels are significantly increased after a relapse or detection of a gadolinium-enhancing lesion and can persist for some time (a few weeks to several months).(9,15,23,58) Other parameters thus far have demonstrated mixed results [e.”
ResultQuintana, E., Coll, C., Salavedra‐Pont, J., Martín, M. M., Robles‐Cedeño, R., Tomàs-Roig, J., Buxó, M., Matute‐Blanch, C., Villar, L. M., Montalbán, X., et al. (2018) · European Journal of Neurology · doi:10.1111/ene.13687 · Cited by 76 · cited 1×
“A small study in 27 patients did not find correlations between sNfL levels and symbol digit modalities test (SDMT) scores after 1 and 10 years, while other studies demonstrated an association between serum and CSF NfL levels and lower verbal fluency performance or SDMT scores.(52,62,63) In one larger study using BICAM…”
ResultBittner, S., Ruck, T., Wiendl, H., Grauer, O. M., & Meuth, S. G. (2016) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285616666741 · Cited by 72
Self-citationCerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis
Gaetani, L., Salvadori, N., Lisetti, V., Eusebi, P., Mancini, A., Gentili, L., Borrelli, A., Portaccio, E., Sarchielli, P., Blennow, K., et al. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09398-7 · Cited by 70 · cited 1×
“Nevertheless, another study confirmed the main finding that CSF NfL is higher in multiple sclerosis patients with cognitive impairment and especially in those with impaired information processing speed and verbal fluency, assessed by the Brief Repeatable Battery of Neuropsychological Tests (BRBN).(64) Another interest…”
ResultSellebjerg, F. T., Royen, L., Sørensen, P. S., Oturai, A. B., & Jensen, P. E. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518794308 · Cited by 70 · cited 2×
“Over a relatively short period, high sNfL levels were associated with an increased risk for relapses and/or EDSS deterioration over the next 1–3 years.(8,21,23,48,49) In a study of patients with multiple sclerosis and healthy controls (n = 259 each), sNfL levels above the 90th percentile of healthy controls predicted…”
BackgroundResultStability of blood‐based biomarkers of Alzheimer's disease over multiple freeze‐thaw cycles
Keshavan, A., Heslegrave, A., Zetterberg, H., & Schott, J. M. (2018) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.06.001 · Cited by 69
Serum neurofilament light chain withstands delayed freezing and repeated thawing
Altmann, P., Leutmezer, F., Zach, H., Wurm, R., Stattmann, M., Ponleitner, M., Petzold, A., Zetterberg, H., Berger, T., Rommer, P., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77098-8 · Cited by 67
Srpová, B., Uher, T., Hrnčiarová, T., Barro, C., Andělová, M., Michalak, Z., Vaněčková, M., Krásenský, J., Nosková, L., Havrdová, E., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458519901272 · Cited by 67 · cited 2×
“It is plausible that high sNfL levels precede visual structural alterations in MRI, while exact time frames are still unclear.(46,49,51) Long-term EDSS progression (45 years) and SPMS conversion + The long-term predictive value of sNfL values is so far not consistent in all studies.”
BackgroundResultSelf-citationHuss, A. M., Otto, M., Şenel, M., Ludolph, A. C., Abdelhak, A., & Tumani, H. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00608 · Cited by 65
Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
Sormani, M. P., Haering, D. A., Kropshofer, H., Leppert, D., Kundu, U., Barro, C., Kappos, L., Tomic, D., & Kuhle, J. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.795 · Cited by 62 · cited 1×
“jects per arm would have been needed to show a 20–40% reduction in sNfL levels.(85) Although the calculated numbers sound realistic, no tri-”
BackgroundCosta, G. D., Martinelli, V., Moiola, L., Sangalli, F., Colombo, B., Finardi, A., Cinque, P. M., Kolb, E., Haghikia, A., Gold, R., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25437 · Cited by 58 · cited 1×
“As one example, patients developing progressive multifocal leukoencephalopathy (PML) on natalizumab treatment had a steeper sNfL increase than those with multiple sclerosis-related relapses.(36) A recent study took advantage of a unique prospective longitudinal serum biobank effort with detailed clinical and demograph…”
Backgroundde Vries, R. M. V. D. V., Wong, Y. Y. M., Mescheriakova, J. Y., van Pelt, E. D., Runia, T. F., Jafari, N., Siepman, T. A. M., Melief, M., Wierenga‐Wolf, A. F., van Luijn, M. M., et al. (2018) · Multiple Sclerosis Journal · doi:10.1177/1352458518775303 · Cited by 52
Aktaş, O., Renner, A., Huss, A. M., Filser, M., Baetge, S. J., Stute, N., Gasis, M., Lepka, K., Goebels, N., Şenel, M., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000885 · Cited by 52
High serum neurofilament associates with diffuse white matter damage in MS
Saraste, M., Bezukladova, S., Matilainen, M., Tuisku, J., Rissanen, E., Sucksdorff, M., Laaksonen, S., Vuorimaa, A., Kühle, J., Leppert, D., et al. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000926 · Cited by 42 · cited 1×
“Indeed, using diffusion tensor imaging as a means to assess diffuse neuroaxonal damage not visible in conventional MRI, it has recently been shown that both T2 lesions and diffuse damage contribute to sNfL levels, and that the latter was preferentially found in older patients with more advanced disease course.(71) The…”
BackgroundSerum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis
Bsteh, G., Berek, K., Hegen, H., Teuchner, B., Buchmann, A., Voortman, M. M., Auer, M., Wurth, S., Zinganell, A., Pauli, F. D., et al. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519882279 · Cited by 39
CSF parvalbumin levels reflect interneuron loss linked with cortical pathology in multiple sclerosis
Magliozzi, R., Pitteri, M., Ziccardi, S., Pisani, A. I., Montibeller, L., Marastoni, D., Rossi, S., Mazziotti, V., Guandalini, M., Dapor, C., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51298 · Cited by 36 · cited 1×
“Parvalbumin is a protein expressed in GABAergic interneurons and has been proposed as a marker of cortical grey matter neurodegeneration in patients with multiple sclerosis.(77,78) A reduction in CSF parvalbumin correlated with meningeal inflammation, cortical lesion load, cortical thickness and cognitive impairment;…”
BackgroundPeng, L., Bi, C., Deyu, X., Mao, L., & Qian, H. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.02.009 · Cited by 35
Blood neurofilament light chain at the doorstep of clinical application
Leppert, D., & Kühle, J. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000599 · Cited by 32 · cited 2×
“sNfL reflected the same benefit with therapy initiation as clinical and MRI parameters.(56,84) Subsequently, a recent study simulated whether”
BackgroundMethodAssociation of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS
Engel, S., Steffen, F., Uphaus, T., Scholz-Kreisel, P., Zipp, F., Bittner, S., & Luessi, F. (2020) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000679 · Cited by 30 · cited 1×
“Patients that are positive for oligoclonal bands have higher serum and CSF NfL levels in comparison with oligoclonal band-negative patients.(74,75) In one study of 142 patients, sNfL values were associated with CSF total CD80 + (i.”
ResultSelf-citationImplementing the 2017 McDonald criteria for the diagnosis of multiple sclerosis
Zipp, F., Oh, J., Fragoso, Y. D., & Waubant, E. L. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0194-0 · Cited by 29
Self-citationFleischer, V., Muthuraman, M., Anwar, A. R., González‐Escamilla, G., Radetz, A., Gracien, R., Bittner, S., Luessi, F., Meuth, S. G., Zipp, F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57895-x · Cited by 28 · cited 1×
“This notion is further supported by pathological concepts preferentially linking grey matter damage and network dysfunction to cognitive impairment.(66,67) Further studies should therefore focus on developing multi-modal approaches integrating sNfL levels with MRI data and other molecular biomarkers indicative of grey…”
BackgroundSelf-citationPreziosa, P., Rocca, M. A., & Filippi, M. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1760846 · Cited by 28 · cited 1×
“Since then, a broad number of studies have confirmed that sNfL values from patients receiving immunomodulatory drugs are generally lower than untreated patients and that initiation of any treatment is associated with a decrease in sNfL levels.(8,9,15,21,24,82,83) Early studies suggest that sNfL levels might be able to…”
BackgroundEngel, S., Friedrich, M., Muthuraman, M., Steffen, F., Poplawski, A., Groppa, S., Bittner, S., Zipp, F., & Luessi, F. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000595 · Cited by 24 · cited 1×
“increased B cell frequency) considerably improved distinction between the groups compared to sNfL alone.(76) As elaborated above, sNfL strongly reflects (focal) acute inflammatory axonal damage of the white matter and its clinical value might be extended by combination with other biomarkers indicating gradual grey mat…”
ResultSelf-citationImaging Markers for Monitoring Disease Activity in Multiple Sclerosis
Suthiphosuwan, S., Kim, D. D., Bharatha, A., & Oh, J. (2017) · Current Treatment Options in Neurology · doi:10.1007/s11940-017-0453-6 · Cited by 10 · cited 1×
“neuroaxonal damage is closely related to clinical and MRI events and prognostication.(1,2) Neurofilament light chain (NfL) is a major”
BackgroundSelf-citationAAN unveils new guidelines for MS disease-modifying therapy
Bittner, S., & Zipp, F. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0026-7 · Cited by 9
Self-citationSerum NFL levels should be used to monitor multiple sclerosis evolution – No
Myhr, K., & Torkildsen, Ø. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519872891 · Cited by 6 · cited 1×
“whether this assumption can be generalized to all concentrations and patient subgroups.(16) The minimally invasive detection in blood samples can be considered a breakthrough for the potential”
BackgroundSerum NFL levels should be used to monitor multiple sclerosis evolution – Commentary
Chitnis, T. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458519880471 · Cited by 6
Cited by
Multiple sclerosis progression: time for a new mechanism-driven framework
Kuhlmann, T., Moccia, M., Coetzee, T., Cohen, J. A., Correale, J., Graves, J., Marrie, R. A., Montalban, X., Yong, V. W., Thompson, A. J., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00289-7 · Cited by 667
Self-citationJakimovski, D., Bittner, S., Zivadinov, R., Morrow, S. A., Benedict, R. H., Zipp, F., & Weinstock-Guttman, B. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01473-3 · Cited by 597
Self-citationNeurofilaments as biomarkers in neurological disorders — towards clinical application
Khalil, M., Teunissen, C. E., Lehmann, S., Otto, M., Piehl, F., Ziemssen, T., Bittner, S., Sormani, M. P., Gattringer, T., Abu-Rumeileh, S., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00955-x · Cited by 446
Self-citationYalachkov, Y., Schäfer, J. H., Jakob, J., Friedauer, L., Steffen, F., Bittner, S., Foerch, C., & Schaller-Paule, M. A. (2023) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200045 · Cited by 49
Self-citationYoussef, P., Hughes, L., Kim, W. S., Halliday, G. M., Lewis, S. J. G., Cooper, A., & Dzamko, N. (2023) · Scientific Reports · doi:10.1038/s41598-023-32480-0 · Cited by 46
Metadata
- Authors
- Bittner, S., Oh, J., Havrdová, E. K., Tintoré, M., & Zipp, F.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-06-28
- Volume
- 144
- Issue
- 10
- Pages
- 2954-2963
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W3175893435
- Cited by
- 229
- References
- 83
- FWCI
- 20.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.